Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling
Sign Up to like & getrecommendations! Published in 2019 at "Journal of General Internal Medicine"
DOI: 10.1007/s11606-019-05460-2
Abstract: Obtaining an accurate understanding of the known benefits and risks of drugs is difficult, particularly when drugs first come to market. The most robust evidence is largely limited to pre-marketing studies (e.g., phase 3 trials),… read more here.
Keywords: reporting drug; benefit; information; drug ... See more keywords